Cathie Wood Invests $4M in Intellia Therapeutics, Trims Stakes in Roku and DraftKings
PorAinvest
sábado, 30 de agosto de 2025, 8:51 pm ET1 min de lectura
ETH--
On Thursday, August 28, 2025, ARK Invest purchased $4 million worth of Intellia Therapeutics shares, adding to its growing position in the gene-editing company. This move underscores ARK's bullish outlook on Intellia's long-term prospects, as the stock has gained over 56% in the past three months [4].
Conversely, ARK has been reducing its exposure to Roku and DraftKings. On the same day, ARK sold 55,624 shares of Roku for about $5.35 million and 54,679 shares of DraftKings for about $2.61 million across three ETFs. These sales continue a pattern of trimming exposure to these companies, suggesting a potential reallocation away from digital sports betting and gaming [4].
ARK's recent trading activities reflect a broader trend of increasing its biotech holdings and expanding its cryptocurrency portfolio. In the past week, ARK purchased $15.6 million worth of Bitmine stock, further bolstering its Ethereum holdings. This acquisition comes as Bitmine's stock has surged over 490% year-to-date, despite a recent dip [5].
Investors and market watchers will be closely monitoring ARK's trades, as they can often influence market sentiment around the targeted stocks. The transparency of ARK's daily trade reports provides unique insights into the investment strategies of one of the most closely followed fund managers in the industry.
References:
[1] https://www.investing.com/news/company-news/cathie-woods-ark-buys-intellia-stock-trims-draftkings-position-93CH-4217460
[2] https://www.tipranks.com/news/cathie-wood-adds-over-11m-in-biotech-stocks-reduces-stakes-in-roku-and-draftkings
[3] https://www.benzinga.com/news/25/08/47374560/cathie-woods-raises-wager-on-ethereum-hoarding-bitmine-ark-buys-stock-of-tom-lee-backed-company-dumps-shares-of-sports-betting-giant
[4] https://www.tipranks.com/news/cathie-wood-invests-4m-in-this-biotech-stock-trims-stakes-in-roku-and-draftkings
[5] https://www.ainvest.com/news/cathie-wood-ark-invest-purchases-15-6m-bitmine-stock-strengthening-ethereum-holdings-2508/
NTLA--
Cathie Wood's ARK Invest has invested $4 million in Intellia Therapeutics, a biotech company, while trimming stakes in Roku and DraftKings. The move highlights ARK's confidence in the biotech sector and potential reallocation away from digital sports betting and gaming. Intellia has gained 56% in the past three months, while Roku and DraftKings shares have risen 31.2% and 29.7% year-to-date, respectively.
Cathie Wood's ARK Invest has made significant moves in its portfolio, indicating a strategic shift towards the biotechnology sector and cryptocurrency markets. The latest trades highlight ARK's confidence in Intellia Therapeutics, a biotech company, while trimming stakes in Roku and DraftKings.On Thursday, August 28, 2025, ARK Invest purchased $4 million worth of Intellia Therapeutics shares, adding to its growing position in the gene-editing company. This move underscores ARK's bullish outlook on Intellia's long-term prospects, as the stock has gained over 56% in the past three months [4].
Conversely, ARK has been reducing its exposure to Roku and DraftKings. On the same day, ARK sold 55,624 shares of Roku for about $5.35 million and 54,679 shares of DraftKings for about $2.61 million across three ETFs. These sales continue a pattern of trimming exposure to these companies, suggesting a potential reallocation away from digital sports betting and gaming [4].
ARK's recent trading activities reflect a broader trend of increasing its biotech holdings and expanding its cryptocurrency portfolio. In the past week, ARK purchased $15.6 million worth of Bitmine stock, further bolstering its Ethereum holdings. This acquisition comes as Bitmine's stock has surged over 490% year-to-date, despite a recent dip [5].
Investors and market watchers will be closely monitoring ARK's trades, as they can often influence market sentiment around the targeted stocks. The transparency of ARK's daily trade reports provides unique insights into the investment strategies of one of the most closely followed fund managers in the industry.
References:
[1] https://www.investing.com/news/company-news/cathie-woods-ark-buys-intellia-stock-trims-draftkings-position-93CH-4217460
[2] https://www.tipranks.com/news/cathie-wood-adds-over-11m-in-biotech-stocks-reduces-stakes-in-roku-and-draftkings
[3] https://www.benzinga.com/news/25/08/47374560/cathie-woods-raises-wager-on-ethereum-hoarding-bitmine-ark-buys-stock-of-tom-lee-backed-company-dumps-shares-of-sports-betting-giant
[4] https://www.tipranks.com/news/cathie-wood-invests-4m-in-this-biotech-stock-trims-stakes-in-roku-and-draftkings
[5] https://www.ainvest.com/news/cathie-wood-ark-invest-purchases-15-6m-bitmine-stock-strengthening-ethereum-holdings-2508/
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios